Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cindy H Chau

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Urology|May 15, 2014
Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention TrialWilliam D Figg, Cindy H Chau, Douglas K Price, et al.
BJU International|February 20, 2013
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancerWilliam L Dahut, Ravi A Madan, Joyson J Karakunnel, et al.
Pharmacotherapy|June 26, 2008
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy researchWilliam D Figg, Cindy H Chau, Richard Okita, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2014
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasmsWilliam D Figg, Manish Monga, Donna Headlee, et al.
Cancer|May 11, 2016
Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention TrialDouglas K Price, Cindy H Chau, Cathee Till, et al.
Journal of Natural Products|May 4, 2016
Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 InteractionAndrew K L Goey, Cindy H Chau, Tristan M Sissung, et al.
The Journal of Urology|October 19, 2010
Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trialDouglas K Price, Cindy H Chau, Cathee Till, et al.
Plos One|May 9, 2015
Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention TrialCindy H Chau, Douglas K Price, Cathee Till, et al.
Scientific Reports|March 12, 2021
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancersSarah E Lochrin, Baris Turkbey, Billel Gasmi, et al.
Cancer Research Communications|July 24, 2025
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC ModelsBenjamin C Brim, Andres F Leon, Erica L Beatson, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Urology|May 15, 2014
Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention TrialWilliam D Figg, Cindy H Chau, Douglas K Price, et al.
BJU International|February 20, 2013
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancerWilliam L Dahut, Ravi A Madan, Joyson J Karakunnel, et al.
Pharmacotherapy|June 26, 2008
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy researchWilliam D Figg, Cindy H Chau, Richard Okita, et al.
Cancer Chemotherapy and Pharmacology|September 4, 2014
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasmsWilliam D Figg, Manish Monga, Donna Headlee, et al.
Cancer|May 11, 2016
Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention TrialDouglas K Price, Cindy H Chau, Cathee Till, et al.
Journal of Natural Products|May 4, 2016
Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 InteractionAndrew K L Goey, Cindy H Chau, Tristan M Sissung, et al.
The Journal of Urology|October 19, 2010
Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trialDouglas K Price, Cindy H Chau, Cathee Till, et al.
Plos One|May 9, 2015
Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention TrialCindy H Chau, Douglas K Price, Cathee Till, et al.
Scientific Reports|March 12, 2021
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancersSarah E Lochrin, Baris Turkbey, Billel Gasmi, et al.
Cancer Research Communications|July 24, 2025
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC ModelsBenjamin C Brim, Andres F Leon, Erica L Beatson, et al.
Pageof 8